Staff

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced...

Predicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection Kit

SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company committed to advancing precision medicine...

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes

FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer

Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early...

Political Prosecution of Steve Bannon and His Conviction Are an Unprecedented Outrage, Declares the Association of American Physicians and Surgeons (AAPS)

TUCSON, Ariz., July 23, 2022 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons (AAPS) decries the political prosecution...

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,...

error: Content is protected !!